Liquid Biopsy

A novel liquid biopsy test can help determine whether patients with oligometastatic non-small cell lung cancer will benefit more from targeted, high-dose radiation instead of drug-based therapy, according to study results.

Circulating tumor DNA genotyping before tissue diagnosis of suspected advanced non-small cell lung cancer resulted in significantly shorter median time to treatment compared with standard tissue testing, study results showed.

Tumor tissue-modified viral-HPV DNA testing demonstrated 100% specificity in both diagnosis and surveillance of HPV-associated oropharyngeal squamous cell carcinoma in a clinical setting, according to a study.

CHICAGO — Long-term follow up shows that response to tepotinib remains robust in patients with MET exon-14 skipping non-small cell lung cancer, according to research presented at ASCO Annual Meeting.

A circulating tumor DNA liquid biopsy can predict the likelihood of early disease progression among patients treated with chimeric antigen receptor T-cell therapy for advanced multiple myeloma, study results showed.

Liquid biopsy effectively predicted survival outcomes among a cohort of patients with various metastatic cancer types, according to study results published in Annals of Oncology.

Nathalie D. Mckenzie, MD, is a gynecologic oncologist and program director of the gynecologic oncology fellowship at AdventHealth Cancer Institute who has spent her career serving patients in countries with limited access to cancer therapies.

Pancreatic cancer is among the deadliest malignancies, and those who specialize in its treatment eagerly embrace any tools that may help extend patient survival.

Often regarded in oncology as a complementary diagnostic or early detection tool, liquid biopsy has moved into routine clinical use to help guide treatment decisions in the era of targeted, molecular-based therapies.

A novel multicancer early detection blood test identified a common signal for more than 50 cancer types and predicted where the signal originated in the body among individuals with undiagnosed cancer.